Conference
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.
Authors
Sternberg CN; Daugaard G; Geczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JMT; Galli L
Volume
32
Pagination
pp. 5061-5061
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.5061
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X